Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM5A | P29375 | 2/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | ASPH | Q12797 | 2/20 | 0.31 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663647 | 1.00 | KDM4C (0.33) | KDM4CALDH1A1KDM5AKDM5BKDM4E | |
| SCHEMBL29813265 | 0.88 | KDM5A (0.30) | KDM5AKDM5B | |
| SCHEMBL17603692 | 0.86 | KDM4E (0.42) | KDM4CALDH1A1KDM5AKDM5BKDM4E | |
| SCHEMBL24833027 | 0.82 | HRH4 (0.36) | NOS3NOS2 | |
| SCHEMBL17603706 | 0.81 | KDM4E (0.49) | KDM4CALDH1A1KDM4EGLAGAA | |
| SCHEMBL25828300 | 0.80 | SMN1; SMN2 (0.35) | KDM4CALDH1A1KDM5AKDM5BKDM4E | |
| SCHEMBL30898769 | 0.77 | NOS3 (0.48) | KDM4CALDH1A1NAPRTNOS3NOS2 | |
| SCHEMBL16414490 | 0.76 | ALDH1A1 (0.44) | KDM4CALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL30590435 | 0.76 | SMN1; SMN2 (0.42) | KDM4CALDH1A1KDM4EKMT2AGABRP | |
| SCHEMBL17619241 | 0.74 | LMNA (0.40) | KDM4CALDH1A1KDM5AKDM4EASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116171155-A | Pyrido [2,3-d ] pyrimidine-2 (1H) -ketone derivative, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2022121839-A1 | PYRIDO[2,3-D]PYRIMIDIN-2(1H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143751-A1 | Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs | TYR, MAPT, DDC | KDM4C 2702/4885ALDH1A1 3131/4885KDM5A 2514/4885 |
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | PDE3A, PDE2A, PDE5A | KDM4C 916/4885ALDH1A1 475/4885KDM5A 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.